OPGN - オプジェン （OpGen Inc.） オプジェンOPGNのチャート
OPGNの企業情報
| symbol | OPGN |
|---|---|
| 会社名 | OpGen Inc （オプジェン） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical Specialities |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 オプジェン（OpGen Inc.）は生命科学のための光学的マッピングソリューションの提供に従事する米国の会社である。同社は微生物、酵母、及び真菌ゲノムアーキテクチャの分析ため光学的マッピングサービスを提供する。その光学的マッピング技術は、生命科学、臨床的及び食品微生物学、生命科学、疫学、薬理学、微生物法医学、製造品質管理、及び応用研究アプリケーションに応用される。同社のマップ解析ソフトウェアモジュールは、100Mb以内の微生物サンプルとゲノムため分析を提供する「Argus」全ゲノムマッピングシステムを含む。 オプジェンは、米国のバイオ企業。医療提供者を支援するために、分子テストや生物情報学を用いて、多剤抵抗性細菌感染症向けに初期商用段階の医薬品を提供。また、全遺伝子解読のための製品やサ―ビスを提供するほか、生命科学のための微生物、植物、動物およびヒト遺伝子の分析を手掛ける。 OpGen, Inc. (Gaithersburg, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with subsidiaries, Curetis GmbH and Ares Genetics GmbH, OpGen is developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen's product portfolio includes Unyvero, Acuitas®AMR Gene Panel and Acuitas® Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. |
| 本社所在地 | 708 Quince Orchard Road Suite 160 Gaithersburg MD 20878 USA |
| 代表者氏名 | Evan Jones エヴァンジョーンズ |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 240-813-1260 |
| 設立年月日 | 36892 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2015年 |
| 従業員数 | － |
| url | www.opgen.com |
| nasdaq_url | https://www.nasdaq.com/symbol/opgn |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -11.73453 |
| 終値（lastsale） | 1.9899 |
| 時価総額（marketcap） | 12359820.1023 |
| 時価総額 | 時価総額（百万ドル） 8.57156 |
| 売上高 | 売上高（百万ドル） 3.37115 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 3.09665 |
| 当期純利益 | 当期純利益（百万ドル） -12.61360 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 OpGen Inc revenues increased 11% to $1.6M. Net loss decreased 31% to $6.4M. Revenues reflect Collaboration revenue increase from $27K to $359K. Lower net loss reflects Interest and other income increase from $0K to $5K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$5.67 to -$1.32. |
OPGNのテクニカル分析
OPGNのニュース
OpGen - Expansion of FIND R&D collaboration 2023/04/06 07:34:00 Finanz Nachrichten
OpGen has announced the expansion of its initial R&D agreement (signed in September 2022) with FIND, a global non-profit alliance for diagnostics, with potential revenue of €830k, roughly €130k hig…
OpGen expands collaboration with FIND 2023/04/05 13:03:39 Seeking Alpha
Precision medicine company, OpGen (OPGN) signed an amendment to its research and development collaboration agreement with FIND, to expand the collaboration which was originally started…
OpGen''s Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND 2023/04/05 11:30:00 Benzinga
Parties add several deliverables to initial R&D collaboration contract Overall potential revenue increased to up to euro 830 thousand ROCKVILLE, Md., April 05, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN , "OpGen" or "the Company")), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that it signed an amendment to its research and development ("R&D") collaboration agreement with FIND , to expand the collaboration which was originally started in fall of 2022. The work already completed under the collaboration will be expanded by three work packages increasing total project volume to up to € 830 thousand in revenue potential. The added deliverables will address the following topics: An Antimicrobial Stewardship Module supporting users with rule-based information to allow making the best treatment choices based on respective hospital''s drug availability; A "Data everywhere" concept, investigating hardware and software options for remote connectivity in the specific environments of low- and middle- income countries (LMICs); and Next Generation Sequencing ("NGS") strain analysis including isolates from several sub-Saharan African countries to investigate any potential sequence differences.
OpGen’s Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND 2023/04/05 11:30:00 Opgen
Parties add several deliverables to initial R&D collaboration contract Overall potential revenue increased to up to euro 830 thousand ROCKVILLE, Md. , April 05, 2023 (GLOBE NEWSWIRE) -- OpGen , Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of
OpGen - Forecasts reset ahead of busy 2023 2023/04/03 11:34:00 Finanz Nachrichten
OpGen''s FY22 update reflected a busy period for the company following the FY22 preliminary update in January 2023. Top-line performance continued to be affected by longer sales cycles, although the…
Why Manchester United Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket 2022/11/23 12:38:52 Benzinga
Gainers COMSovereign Holding Corp. (NASDAQ: COMS ) shares rose 58.4% to $0.1069 in pre-market trading after gaining more than 16% on Tuesday. Kalera Public Limited Company (NASDAQ: KAL ) rose 30% to $0.1183 in pre-market trading after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share. OpGen, Inc. (NASDAQ: OPGN ) rose 19.2% to $0.23 in pre-market trading after declining around 10% on Tuesday. The company recently posted downbeat quarterly results. Cosmos Holdings Inc.. (NASDAQ: COSM ) rose 19.1% to $0.3899 in pre-market trading after surging around 87% on Tuesday. Cosmos Holdings recently posted a Q3 loss of $0.08 per share. Core Scientific, Inc. (NASDAQ: CORZ ) rose 18.9% to $0.1596 in pre-market trading after declining 20% on Tuesday. Golden Sun Education Group Limited (NASDAQ: GSUN ) rose 17.2% to $2.38 in pre-market trading. Venus Concept Inc. (NASDAQ: VERO ) shares rose 15.3% to $0.2522 in pre-market trading after climbing over 9% on Tuesday. Venus Concept recently announced completion of $6.72 million private placement financing.
OPGN (OpGen Inc.) has powerful results 2022/11/11 13:48:00 US Post News
OpGen Inc. (NASDAQ:OPGN) marked $0.19 per share on Thursday, up from a previous closing price of $0.18. While OpGen Inc. has overperformed by 4.17%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, OPGN fell by -89.12%, with highs and lows ranging from $1.76 to $0.16, whereas […]
OpGen, Inc. (OPGN) Q3 2022 Earnings Call Transcript 2022/11/11 04:29:01 Seeking Alpha
OpGen, Inc. (NASDAQ:NASDAQ:OPGN) Q3 2022 Earnings Conference Call November 10, 2022 16:30 ET Company Participants Alyssa Factor - Investor Relations Associate, Edison Group Oliver Schacht -…
OpGen GAAP EPS of -$0.30 misses by $0.19, revenue of $448.71M beats by $447.41M 2022/11/10 21:25:34 Seeking Alpha
OpGen press release (OPGN): Q3 GAAP EPS of -$0.30 misses by $0.19.Revenue of $448.71M (+36086.3% Y/Y) beats by $447.41M.Cash and cash equivalents were approximately $10.3 million as…
OpGen Reports Third Quarter 2022 Financial Results and Provides Business Update 2022/11/10 21:10:00 GlobeNewswire
ROCKVILLE, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its third quarter 2022 financial and operating results. Management will host an investor call to discuss quarterly results and provide a business update.
Why Manchester United Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket 2022/11/23 12:38:52 Benzinga
Gainers COMSovereign Holding Corp. (NASDAQ: COMS ) shares rose 58.4% to $0.1069 in pre-market trading after gaining more than 16% on Tuesday. Kalera Public Limited Company (NASDAQ: KAL ) rose 30% to $0.1183 in pre-market trading after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share. OpGen, Inc. (NASDAQ: OPGN ) rose 19.2% to $0.23 in pre-market trading after declining around 10% on Tuesday. The company recently posted downbeat quarterly results. Cosmos Holdings Inc.. (NASDAQ: COSM ) rose 19.1% to $0.3899 in pre-market trading after surging around 87% on Tuesday. Cosmos Holdings recently posted a Q3 loss of $0.08 per share. Core Scientific, Inc. (NASDAQ: CORZ ) rose 18.9% to $0.1596 in pre-market trading after declining 20% on Tuesday. Golden Sun Education Group Limited (NASDAQ: GSUN ) rose 17.2% to $2.38 in pre-market trading. Venus Concept Inc. (NASDAQ: VERO ) shares rose 15.3% to $0.2522 in pre-market trading after climbing over 9% on Tuesday. Venus Concept recently announced completion of $6.72 million private placement financing.
OPGN (OpGen Inc.) has powerful results 2022/11/11 13:48:00 US Post News
OpGen Inc. (NASDAQ:OPGN) marked $0.19 per share on Thursday, up from a previous closing price of $0.18. While OpGen Inc. has overperformed by 4.17%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, OPGN fell by -89.12%, with highs and lows ranging from $1.76 to $0.16, whereas […]
OpGen, Inc. (OPGN) Q3 2022 Earnings Call Transcript 2022/11/11 04:29:01 Seeking Alpha
OpGen, Inc. (NASDAQ:NASDAQ:OPGN) Q3 2022 Earnings Conference Call November 10, 2022 16:30 ET Company Participants Alyssa Factor - Investor Relations Associate, Edison Group Oliver Schacht -…
OpGen GAAP EPS of -$0.30 misses by $0.19, revenue of $448.71M beats by $447.41M 2022/11/10 21:25:34 Seeking Alpha
OpGen press release (OPGN): Q3 GAAP EPS of -$0.30 misses by $0.19.Revenue of $448.71M (+36086.3% Y/Y) beats by $447.41M.Cash and cash equivalents were approximately $10.3 million as…
OpGen Reports Third Quarter 2022 Financial Results and Provides Business Update 2022/11/10 21:10:00 GlobeNewswire
ROCKVILLE, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its third quarter 2022 financial and operating results. Management will host an investor call to discuss quarterly results and provide a business update.